SIM
NBIX icon

Sonora Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Sonora Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$10K Hold
100
– – ﹤0.01% 782
2021
Q2 		$10K Hold
100
– – ﹤0.01% 715
2021
Q1 		$10K Hold
100
– – ﹤0.01% 1283
2020
Q4 		$10K Hold
100
– – ﹤0.01% 1227
2020
Q3 		$10K Sell
100
-8
-7% -$925 ﹤0.01% 1211
2020
Q2 		$13K Buy
108
+8
+8% +$884 ﹤0.01% 948
2020
Q1 		$9K Hold
100
– – ﹤0.01% 1124
2019
Q4 		$11K Hold
100
– – ﹤0.01% 1131
2019
Q3 		$9K Hold
100
– – ﹤0.01% 1268
2019
Q2 		$8K Hold
100
– – ﹤0.01% 1263
2019
Q1 		$9K Hold
100
– – ﹤0.01% 1097
2018
Q4 		$7K Hold
100
– – ﹤0.01% 958
2018
Q3 		$12K Hold
100
– – ﹤0.01% 798
2018
Q2 		$10K Hold
100
– – ﹤0.01% 808
2018
Q1 		$8.29K Hold
100
– – ﹤0.01% 844
2017
Q4 		$7.76K Hold
100
– – ﹤0.01% 867
2017
Q3 		$6.13K Hold
100
– – ﹤0.01% 820
2017
Q2 		$4.6K Sell
100
-100
-50% -$4.85K ﹤0.01% 849
2017
Q1 		$8.66K Buy
+200
New +$8.57K ﹤0.01% 718

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Sonora Investment Management's NBIX Position: Q3 2021 in Review

Sonora Investment Management held its Neurocrine Biosciences (NBIX) position steady in Q3 2021 at 100 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #782.

Sonora Investment Management first reported a position in NBIX in Q1 2017 and has held it in 19 quarters since. The position peaked at $13K in Q2 2020. 396 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Sonora Investment Management held 100 shares of Neurocrine Biosciences worth $10K as of Q3 2021.
  • Sonora Investment Management left its Neurocrine Biosciences share count unchanged in Q3 2021.
  • Neurocrine Biosciences made up ﹤0.01% of Sonora Investment Management's portfolio in Q3 2021, its #782 holding.
  • Sonora Investment Management first reported a position in Neurocrine Biosciences in Q1 2017 and has held it in 19 quarters since.
  • Sonora Investment Management's Neurocrine Biosciences position peaked at $13K in Q2 2020.
  • 396 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Sonora Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.